Clinical Trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Name: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS — clinical trial record (NCT06692491)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SPRING

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

Trial Details

NCT Number	NCT06692491
Lead Sponsor	Peking University Shenzhen Hospital
Conditions	Rare Tumour
Enrollment	200 participants
Start Date	2025-01-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-18